Journal of Clinical Oncology
Articles in this Issue
Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients.
261 Background: Clinicians use next-generation sequencing (NGS) to tailor targeted treatments for PCa patients. However, the results are often available i...
VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.
TPS616 Background: Despite substantial advances in therapy over the past 20 years, the median progression-free survival (mPFS) for advanced RCC patients t...
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).
708 Background: This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in metastatic urothelial carcinoma (mUC) patients...
Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.
235 Background: Bavdegalutamide (bavdeg; formerly ARV-110) is a first-in-class oral proteolysis targeting chimera (PROTAC) protein degrader that selective...
[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients.
34 Background: Prostate cancer represents a strong economic and social burden in the world. Imaging, pathology report and prostate specific antigen are th...
Evaluation of avelumab first-line (1L) maintenance therapy and subsequent treatment (tx) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) using a large claims database in Japan: JAVEMACS-D.
700 Background: In Japan, avelumab was approved in Feb 2021 as maintenance therapy for pts with curatively unresectable UC that had not progressed after p...
Phase Ib/II clinical trial of oncolytic virus intravesical irrigation for preventing recurrence after TURBT in patients with recurrent high-risk NMIBC.
763 Background: Oncolytic virus therapy represents a novel approach in cancer treatment, showing promising results in non-muscle-invasive bladder cancer (...
Multivisceral surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.
176 Background: Local complications due to infiltration and compression of adjacent organs represent significant complications of locally advanced castrat...
Assessment of pathologic responses from unstructured pathology reports using large language models.
866 Background: Emerging data suggests that Language Models (LLMs) provide an unprecedented opportunity to extract critical data from the unstructured pat...
Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment.
123 Background: Lutetium-177 vipivotide tetraxetan (Lu177) is the first FDA-approved radioligand therapy for PSMA-positive metastatic castration-resistant...
Health-related quality of life in patients with metastatic prostate cancer: Results from an international real-world survey.
106 Background: Although novel treatments (tx) for metastatic prostate cancer (PC) are prolonging patient (pt) overall survival, data are limited on disea...
Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.
716 Background: Nadofaragene firadenovec is an FDA-approved gene therapy for Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cance...
Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer.
185 Background: Targeted radionucleotide therapy (TRT) has become a standard of care. α-emitters have a higher energy transfer over a shorter range than β...
Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.
340 Background: Prostate cancer (PCa) is the most commonly diagnosed cancer in men, and early detection is crucial for better patient outcomes. This study...
Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
778 Background: Immune checkpoint inhibitors have a substantial and growing role in all stages of care for bladder cancer. Durvalumab (Durva) is a humanis...
GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.
374 Background: Preliminary evidence from preclinical and observational data suggests that GLP-1 receptor agonists (GLP-1RAs) may reduce prostate cancer (...
Timely next-generation sequencing testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare.
320 Background: Next-Generation Sequencing (NGS) testing has become a cornerstone of personalized medicine in cancer care. With Medicare Advantage (MA) no...
DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.
853 Background: DNA damage repair gene alterations (DDRa), especially ERCC2 mutations, have been associated with improved clinical...
Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
543 Background: We previously reported that combining CBM588 ( Clostridium butyricum MIYAIRI588), a live bacterial product, with c...
Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.
749 Background: Outcome benefit associated with lymph node dissection (LND) at time of radical cystectomy have been suggested in urothelial bladder cancer...
Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
549 Background: In the phase 2 LITESPARK-003 study (NCT03634540), belzutifan plus cabozantinib showed antitumor activity in patients with advanced ccRCC w...
Evaluating the rates of surgical overtreatment of prostate cancer.
357 Background: Overtreatment of prostate cancer is a public health concern and a barrier to prostate cancer screening. In 2012 the US Preventative Task F...
Biomarker analysis in localized urothelial cancer DUART patients post-treatment.
859 Background: Patients with localized unresectable or cisplatin-ineligible urothelial cancer (UC) have limited treatment options. Biomarker identificati...
Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma.
582 Background: Kidney injury molecule-1 (KIM-1) is overexpressed in clear cell and papillary renal cell carcinoma (RCC) and in proximal tubular kidney in...
Efficacy of <sup>177</sup> Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.
121 Background: In the Phase 3 VISION trial, treatment with the prostate-specific membrane antigen (PSMA)-targeted radioli...